CCO Management Series
Choosing First-Line Therapy in Chronic Hepatitis B
Module
Management of Hepatitis B: Understanding Treatment Candidacy and Factors for Selecting Initial Therapy
- Kris V. Kowdley, MD, FACP
|
|
|
Kris V. Kowdley, MD, FACP, discusses the determinants for treatment candidacy, the goals of HBV therapy, and factors for selecting first-line treatment in hepatitis B.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the goals of hepatitis B virus (HBV) therapy in hepatitis B e antigen (HBeAg)–negative and HBeAg-positive hepatitis B patients
- Summarize the efficacy data for currently available HBV therapies
- Discuss the factors for selecting optimal first-line therapy in hepatitis B patients
|
Interactive Case Challenges
Treatment of an HBeAg-Negative 47-Year-Old Man Presenting Following Routine Screening for Hepatitis B
|
|
|
Test your ability to manage frontline treatment of an asymptomatic 47-year-old Asian male with chronic hepatitis B.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall guidelines for determining treatment candidacy in treatment-naive patients with HBeAg-negative chronic hepatitis B
- Describe factors involved in selecting first-line therapy for hepatitis B
- Discuss management of virologic resistance in patients with chronic hepatitis B
|
Management of a 38-Year-Old HBeAg-Positive Asian American Man Seeking First-Line Treatment for Hepatitis B
|
|
|
Norah Terrault, MD, MPH, describes the factors underlying first-line treatment decisions in HBeAg-positive patients with chronic hepatitis B.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe criteria for selecting optimal first-line therapy in HBeAg-positive patients
- Discuss strategies for managing resistance in HBeAg-positive patients
- Recount data regarding the optimal duration of treatment and posttreatment monitoring strategies in HBeAg-positive patients
|
Virtual Presentation
Choosing First-Line Therapy in Chronic Hepatitis B
- Emmet B. Keeffe, MD, MACP
|
|
|
Emmet B. Keeffe, MD, MACP, discusses factors involved in selecting first-line therapy for chronic hepatitis B by reviewing 3 typical patient cases.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount clinical data on available therapies for the treatment of chronic hepatitis B
- Describe the key factors used in making decisions regarding first-line treatment in patients with chronic hepatitis B
- Discuss the clinical situations in which each available HBV therapy would be the most appropriate choice for first-line treatment
|
Slideset: Choosing First-Line Therapy in Chronic Hepatitis B
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 843 KB
| Date posted: 7/5/2007
|
Disclaimer:
The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|